Increased cerebrospinal fluid cleaved tau protein (C-tau) levels suggest axonal damage in pediatric patients with brain tumors

Cengiz, Pelin; Zemlan, Frank P.; Eickhoff, Jens; Ellenbogen, Richard G.; Zimmerman, Jerry J.

doi:10.1007/s00381-015-2705-7

Cited by 8 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, CSF was not analyzed in that study. It should be noted that alterations in HODE levels are not restricted to MS. As for reports on HODE levels in CSF in other neurological diseases, 9-HODE levels in children with brain tumors 22 and hydrocephalus 23 did not differ from controls. Outside the central nervous system, HODEs have been implicated in various contexts, e.g.…”

Section: Discussionsupporting

confidence: 56%

Oxylipins in cerebrospinal fluid in clinically isolated syndrome and relapsing remitting multiple sclerosis

Håkansson

Gouveia-Figueira

Ernerudh

et al. 2018

Prostaglandins & Other Lipid Mediators

View full text Add to dashboard Cite

Although oxylipins are involved in inflammation, data on these lipid mediators in multiple sclerosis are sparse. In this study, a panel of oxylipins were analysed swith liquid chromatography tandem mass spectrometry in cerebrospinal fluid (CSF) from 41 treatment naïve patients with clinically isolated syndrome (CIS) or relapsing remitting MS (RRMS) and 22 healthy controls. CSF levels of 9-hydroxyoctadecadienoic acid (9-HODE) and 13-hydroxyoctadecadienoic acid (13-HODE) were significantly higher in patients than in healthy controls (9-HODE median 380 nM (interquartile range 330-450 nM) in patients and 290 nM (interquartile range 250-340 nM) in controls, 13-HODE median 930 nM (interquartile range 810-1080 nM) in patients and 690 nM (interquartile range 570-760 nM) in controls, p < 0.001 in Mann-Whitney U tests). 9-HODE and 13-HODE performed well for separation of patients and healthy controls (AUC 0.85 and 0.88, respectively, in ROC curve analysis). However, baseline CSF levels of the oxylipins did not differ between patients with signs of disease activity during one, two and four years of follow-up and patients without. In conclusion, this study indicates that 9-HODE and 13-HODE levels are increased in CSF from CIS and RRMS patients compared with healthy controls, but does not support 9-HODE or 13-HODE as prognostic biomarkers of disease activity in patients during follow-up.

show abstract

Section: Discussionsupporting

confidence: 56%

Oxylipins in cerebrospinal fluid in clinically isolated syndrome and relapsing remitting multiple sclerosis

Håkansson

Gouveia-Figueira

Ernerudh

et al. 2018

Prostaglandins & Other Lipid Mediators

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this is the first report of such a correlation between Tau serum level and the presence of a brain tumor. So far, only one report has been published of an association between the levels of Tau in CSF and brain tumors in pediatric patients [36, 45], while several reports of correlations with Tau have been published for other non-neurodegenerative disorders, including traumatic brain injury (TBI) [34, 33] and stroke [46]. In TBI, the serum level of Tau was associated with the presence of macroscopic lesions detectable on brain imaging, and with the patients’ clinical outcome [33].…”

Section: Discussionmentioning

confidence: 99%

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases

et al. 2019

View full text Add to dashboard Cite

BackgroundMetastatic breast cancer (MBC) prognosis is variable, depending on several clinical and biological factors. A better prediction of a patient’s outcome could allow for a more accurate choice of treatments. The role of serum biomarkers in predicting outcome remains unclear in this setting. Tau, a microtubule-associated protein, is a neuronal marker that is also expressed in normal breast epithelial cells and cancer cells. Its tissue expression is associated with prognosis in MBC. However, the prognostic value of Tau serum levels in these patients is unknown. We aimed at evaluating the prognostic value of Tau (and other classical biomarkers) in MBC patients, and to assess its association with the presence of brain metastases (BM).Methods244 MBC patients treated at our institution (2007–2015) were retrospectively selected. The usual MBC clinical and pathological variables were collected, altogether with CA15–3, CEA and HER2 extra-cellular domain (ECD) serum levels. Tau serum levels were measured with a novel immunoassay (digital ELISA) using Single Molecule Array (Simoa) technology. Overall survival (OS) was estimated with the Kaplan-Meier method. To investigate prognostic factors, a multivariate analysis was performed. Cut-offs were set using the Youden index method associated with receiver-operating characteristics (ROC) curves to evaluate the accuracy of biomarkers to identify patients with BM.ResultsWith a median follow-up of 40.8 months, median OS was 15.5 months (95%CI 12.4–20.2). Elevated serum levels of Tau were independently associated with a poor outcome in the whole population as well as in patients with (n = 86) and without BM (n = 158). Median serum Tau levels tended to be higher in patients with BM (p = 0.23). In univariate analysis, patients with BM had an increased risk of serum Tau > 3.17 pg/mL (OR = 2.2, p = 0.049). In multivariate analysis, high values of Tau (OR = 3.98, p = 0.034) accurately identified patients with BM in our cohort.ConclusionsTau is a new biomarker of interest in MBC. Its serum level could represent an independent prognostic factor in these patients (both with and without BM). It also seems to be associated with the presence of BM. A validation of these results in an independent set of MBC patients is necessary to confirm these findings.Electronic supplementary materialThe online version of this article (10.1186/s12885-019-5287-z) contains supplementary material, which is available to authorized users.

show abstract

“…74) A prospective clinical observational study demonstrated that children with newly diagnosed brain tumors exhibit markedly elevated CSF cleaved tau levels, which were suggestive of axonal damage. 76) Prostaglandin D2 synthase (PGD2S) levels were six-fold lower in the pediatric tumor samples versus control samples in study by Rajagopal et al 77) The authors speculated that the reduction is a host response to the presence of the tumor. 77) PGD2S is a glycoprotein that is abundant in the CSF and is synthesized and secreted by both glial cells and the choroid plexus.…”

Section: A C C E P T E Dmentioning

confidence: 99%

“…They reported that the 3-methoxy-4-hydroxyphenylglycol level of the CSF was significantly higher in pediatric patients with astrocytoma than in those with medulloblastoma [ 74 ]. A prospective clinical observational study demonstrated that children with newly diagnosed brain tumors exhibit markedly elevated CSF cleaved tau levels, which were suggestive of axonal damage [ 76 ].…”

Section: Csf Biomarkers Of Pediatric Neurological Disordersmentioning

confidence: 99%

Promising candidate cerebrospinal fluid biomarkers of seizure disorder, infection, inflammation, tumor, and traumatic brain injury in pediatric patients

Kim

Chae

2022

Clin Exp Pediatr

View full text Add to dashboard Cite

show abstract

Increased cerebrospinal fluid cleaved tau protein (C-tau) levels suggest axonal damage in pediatric patients with brain tumors

Cited by 8 publications

References 40 publications

Oxylipins in cerebrospinal fluid in clinically isolated syndrome and relapsing remitting multiple sclerosis

Oxylipins in cerebrospinal fluid in clinically isolated syndrome and relapsing remitting multiple sclerosis

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases

Promising candidate cerebrospinal fluid biomarkers of seizure disorder, infection, inflammation, tumor, and traumatic brain injury in pediatric patients

Contact Info

Product

Resources

About